Loading clinical trials...

Pulmonary Hypertension in Left Heart Disease | Clinical Trials | Clareo Health

RECRUITING

Pulmonary Hypertension in Left Heart Disease

Comparison of Noninvasively-Obtained Echocardiographic Doppler Parameters With Simultaneously-Measured Invasive Hemodynamics in Patients Referred for Right Heart Catheterization

NCT05935605•Mayo Clinic

View on ClinicalTrials.gov

Summary

The goal is to compare patients with and without varying severity of pulmonary vascular disease based upon hemodynamic signatures, echocardiographic measures, and lung ultrasound, in tandem with expired gas metabolic testing and blood sampling.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients referred to the cardiac catheterization laboratory for invasive right heart catheterization for any reason.
•Left Heart Disease, defined as one (or more) of the following:
•* Symptomatic HFpEF, defined by signs and symptoms of HF (dyspnea, fatigue), normal left ventricular (LV) EF (≥50% within 12 months of enrollment), and objective evidence of HF fulfilling at least one of the following criteria: Prior hospitalization for decompensated HF treated with intravenous diuretics; Invasively verified HFpEF defined by pulmonary capillary wedge pressure (PCWP) of ≥15 mmHg at rest and/or ≥25 mmHg during exercise; Clinical diagnosis of HFpEF that does not meet criteria i. or ii. but verified with NTproBNP\>300 pg/ml in sinus rhythm or \>900 pg/ml in AF; H2FPEF score ≥6 or HFA-PEFF score≥5 according to current guidelines.
•* Symptomatic HFrEF, defined by defined by signs and symptoms of HF (dyspnea, fatigue) and reduced EF (\<50%).
•* Symptomatic valvular heart disease (VHD), defined by signs and symptoms of HF (dyspnea, fatigue) in tandem with clinically significant aortic or mitral valve disease (regurgitation and/or stenosis).

Exclusion Criteria

•Patient inability or unwillingness to undergo noninvasive echocardiography, or if echocardiography would, in the opinion of the investigator, somehow compromise the quality of data acquisition for the clinical case.
•WSPH Group 1 Pulmonary hypertension or PH (Pulmonary arterial hypertension; including congenital heart disease)
•Group 3 PH (Hypoxia/Lung disease-related PH)
•Group 4 PH (Thromboembolic PH)
•Group 5 PH (Miscellaneous)
•Clinically significant parenchymal lung disease, hypoxemia, or lung infection
•Amyloid/infiltrative cardiomyopathy
•Acute Myocarditis
•Acute coronary syndrome or revascularization within 90 days
•Use of PH-specific drugs
+7 more criteria

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Key Dates

Start Date

July 20, 2023

Primary Completion Date

May 1, 2028

Completion Date

May 1, 2028

Last Updated

March 5, 2026

Enrollment

3,000

ESTIMATED participants

Conditions

Pulmonary HypertensionPulmonary Vascular DiseaseLeft Heart Disease

Interventions

Transthoracic Echocardiography (TTE)

DIAGNOSTIC_TEST

Lung ultrasound

DIAGNOSTIC_TEST

Contacts

Circulatory Failure Research Team

CONTACT

(507) 255-2200 Fuenffinger.Annabelle@mayo.edu

Barry Borlaug, MD

CONTACT

(507) 255-4152 Borlaug.Barry@mayo.edu

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820

Pulmonary Hypertension

View study

RECRUITINGPHASE1

Preliminary Human Trials of F230 Tablets

NCT06899815

Pulmonary Hypertension

View study

RECRUITINGPHASE2/PHASE3

Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 5, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pulmonary Hypertension in Left Heart Disease

Inclusion Criteria

Exclusion Criteria

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Preliminary Human Trials of F230 Tablets

Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

Prospective Evaluation of AI-ECG for SHD Detection

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF